We would love to hear your thoughts about our site and services, please take our survey here.
A month into 2024, the tech IPO calendar remains blank. But after two years of quiet, biotech IPOs are suddenly making noise.
Last week, bladder cancer drug developer CG Oncology priced its IPO above the expected range and raised $380 million. Its shares then jumped 96% on the first day of trading. That offering was followed by Arrivent Biopharma, which raised $175 million and has traded up in price since its IPO.
Alto Neuroscience and Fractyl Health, two other biotech companies, are also planning imminent public debuts.
US listing of Avacta therapeutics next ? with newly appointed US based Head of Therapeutics ready to drive the AVA platform to a whole new valuation, all her friends at the major Pharma's at the upcoming AACR conference will all have their chequebooks ready!
Amazing what is being produced on the boards.
Just do your research, read the results being published, look what the majors are all saying.
Precision medicine
Gene therapy
AI
Several biotech stocks have done IPO's.
IPO's etc are all a gift at current levels.
They all require one thing: patience and being able to buy and wait.
You will all look clever very soon.
Upcoming conference in early April will have one theme only :M&A
Majors have cash, which one will act first.
Eli Lilly bought Point Pharma, which one is next.
Ignore the shorts, buy as much as you can at current levels, before they do.
Good luck
With upcoming news flow from AVA6000 and indeed AVA3996/ AVA2727D a complete re-rating of the therapeutic business is very likely and hence the current share price is a gift and the company come Q2 will be a very exciting therapeutic company with an incredible news flow ahead.
Worth reminding us that GenScript ProBio Signed CDMO Supply Agreement And Formed Strategic Partnership with AffyXell Therapeutics – A Joint Daewong-Avacta venture .GenScript also acquired more equity as well.At what valuation ? Ref Avacta's nil cost 20% holding.
Would be interesting to know at what valuation was their recent stake acquired at?
Read across to Avacta's nil cost holding in Affyxell !
Precision medicine was the talk of the town, especially on day three of the 2024 JPM conference.
It was very clear that precision medicine was one of the buzzwords at the 2024 JPM convention, along with artificial intelligence (AI).
AI in drug discovery is set to reach $5 billion in the next four years, as the technology aims to develop drugs quicker and cheaper.
There was also an heightened interest in AI and precision medicine directly, with a lot of interest AI-based soluble TCR therapeutics platform, which is generating precision medicines for oncology and auto-immune diseases,”.
AI in drug discovery is set to reach $5 billion in the next four years, as the technology aims to develop drugs quicker and cheaper.
From Vox Markets
https://www.voxmarkets.co.uk/articles/vox-markets-fund-manager-series-gervais-williams-of-premier-miton-d6fb11c
The timing of this appointment is the clearest sign that the Therapeutic business carries top priority for Avacta and that AVA6000 will soon make more headlines and valuation of global Precision is going north pre ACCR.
Also worth reminding ourselves head therapeutics lives in the States!